Does disruption of mutated BRAF signaling modulate thyroid cancer phenotype?
These findings support further evaluation of combinational therapy that includes BRAFV600E inhibitors in thyroid cancer patients harboring the BRAFV600E mutation.
Higher NLR, an emerging marker of inflammation, is associated with thromboembolic stroke in non-valvular AF patients.